Forta Bio

ODC™: Targeted DNA/RNA Medicines with Cell Selectivity + Cytotoxicity + Immune Modulation for Cancer, Autoimmunity & Inflammation

Zoya Gluzman-Poltorak, PhD MBA
CEO and Co-Founder
February 11, 2026

A Dedicated Team with a Track Record of Execution and Value Creation

Dr. Zoya Gluzman-Poltorak
CEO & Co-Founder

- 25+ years Biotech Executive
- 7 INDs, $250M+ funding
- BARDA, DoD, NIH contracts

Dr. Valeria Povolotsky
CBO & Co-Founder

- 25+ years Pharma Executive
- 30+ strategic deals
- BD, Partnering, Alliances

Prof. Marcin Kortylewski
Co-Founder & Scientific Lead

- 100+ publications, global KOL
- 20+ patents, ~$20mln Grants
- Serial entrepreneur, 2 INDs

The Unmet Need: Durable Control Without Collateral Damage

Oncology

Autoimmune / Inflammation

Cancer: **$252B**

Immunology: **$180B**

ODC™: Dual Selectivity & Immune Modulation

A single programmable oligo with 3 integrated functions: targeted uptake, conditional elimination, and immunomodulation

- **Targeting domain**
  Drives cell-selective uptake
- **Immunomodulatory sequence**
  Restores immune balance
- **Cytotoxic payload (6tdG)**
  Selective DNA damage in target cells

1. Targeting & Entry



Selective uptake into pathogenic cells

2. Conditional Activation & Kill



Activation only in target context → DNA damage → cell death

3. Immune Reprogramming

Rebalance immune function for durable control

ODC™

ADC



- **Simpler chemistry** – faster, cost-effective (**COGS 1%** vs. 25%), scalable
- **Higher payload density** – more drug per molecule
- **Dual specificity**– targeting domain + TERT activation
- **Dual MoA** – cytotoxicity+ immunomodulation
- **Programmable / modular** – adaptable to many payloads

Telomerase (TERT) is active in ~90% cancers, autoreactive lymphocytes, and inflamed stroma

Broad ODC™ Platform, Focused Clinical Path: FORTA-02

Platform	Product	Program	Disease	Discovery	Preclinical	IND-enabling	Phase I/II
FortaOnc™	FORTA-02	FORTA-022*	Acute Myeloid leukemia (AML)				
		FORTA-021*	Orphan Lymphomas				
		FORTA-023*	Solid Tumor- Basket (Prostate, Kidney, other)				
FortaReg™	FORTA-01	FORTA-011	Autoimmune Nephropathies				
FortaApt™	FORTA-03	FORTA-031	Glioma (Glioblastoma)				

FORTA-02 : Validated MoA, Strong Preclinical Efficacy and Safety, Clear Path to the Clinic

1. **Clinically validated targeting and cytotoxic domains**
2. **Robust and superior *in vivo* efficacy,** replicated in >**12 PoC animal models** in **~630** animals across multiple cancers (AML, B-cell Lymphoma, Prostate, Glioma)
3. **Exceptional safety profile** in humanized HSC mice

Long Term Survival in Systemic AML model



H&E Histology



Immunohistochemistry



Immune infiltration

Unpublished and Yu C. et al., Molecular Therapy (2025)

Accelerates Discovery from Years to Months

FortaApt™

Validation Completed

1. **Glioma**: Targeted delivery of FORTA-03-Apt1 into orthotopic glioma mouse model after a single IV injection
2. **Bone Marrow**

10^{15} Proprietary
Oligo Library



Barcoded
Forta-Aptamer-6tdGO
Libraries

FortaGuideAI™



1. In-vitro high-throughput screening (HTS)

2. In-vivo selection



Targeting	Liver, Lung, Kidney, CNS, Microglia, Fibroblasts, Endothelial cells, any pathogenic TERT+ cells

$15M to Reach Clinical POC within 24 Months in Oncology

Single FORTA-02 product → multiple oncology programs (FORTA-022, FORTA-023)

Program	Activity	Q1-26	Q2-26	Q3-26	Q4-26	Q1-27	Q2-27	Q3-27	Q4-27
Forta Bio's Burn Rate ($K/Q)		**$750K**	**$1,000K**	**$1,750K**	**$1,500K**	**$2,000K**	**$2,000K**	**$3,000K**	**$3,000K**
FORTA-022 AML **OR** **FORTA-023** Solid Tumors **Basket Design** (Prostate, Bladder, Kidney, Colorectal, etc.)	Regulatory	Orphan	Pre-IND		IND				
	IND-enabling	DRF		Tox					
	CMC	PD			GMP				
	Clinical					Dosing			Clinical POC

Accelerated Development: Clinical POC in <24 Months

Ready to scale up



✔ **$1.7M** non-dilutive COH grants (NIH, DoD)

✔ **IP:**
- Exclusive COH IP licensed out
- Forta's new IP filed

✔ **Non-Dilutive:**
- >$3M Grants and Partnerships in process

✔ **Established Collaborations:**
- Tox labs
- Analytical labs
- Manufacturing
- Clinical

✔ **"Orphan First" - Regulatory Strategy**

The Forta Bio Investment Thesis: Redefining Precision Medicine



Novel Platform

First-in-class synthetic and programmable **ODC™** technology with a **dual selectivity** & **immune reprogramming** for unparalleled precision and safety.

Compelling Proof

Robust IND-enabling preclinical data demonstrating superior efficacy and exceptional safety profile in **12** aggressive cancer animal models and humanized HSC mice (~**630** animals)

Scalable Pipeline &AI Engine

Three distinct therapeutic platforms, powered by a proprietary AI engine that creates a sustainable discovery and optimization advantage.

World-Class Team

Led by proven industry veterans with a track record of advancing products to the clinic, securing funding, and executing strategic deals.

Clear Path to Value

A capital-efficient plan to use **$15M** to Clinical POC in **24 months**, significantly de-risking the asset and creating a major value inflection point.

Let's begin the conversation.

Zoya Gluzman-Poltorak, PhD, MBA
CEO & Co-Founder
zoya@forta.bio
+1-626-497-0627

Valeria Povolotsky, PhD
CBO & Co-Founder
valeria@forta.bio
+1-973-780-7988

www.forta.bio

	FortaReg™	FortaOnc™	FortaApt™
			
	Indications: • B-cell Autoimmune Diseases (e.g. AI Nephropathies) • Endometriosis	**Indications:** • Acute Myeloid Leukemia • B-Cell Lymphoma • Prostate Cancer • Kidney Cancer • Lung Cancer • Ovarian Cancer • Other Solid Tumors	**Indications:** • Glioma • Other Solid Tumors • Autoimmune Disorders (also CNS) • Age-related Fibrosis • Endometriosis
Targeting	**Scavenger Receptors**	**Scavenger Receptors**	**Any targets**
Direct Effect	Autoreactive B-cell depletion	Tumor cells depletion	Any TERT^{+} cells depletion
Immune Effect	Immune Tolerance Restoration (Tregs)	Immune Activation (CD8^{+} T-cells, NK, APC)	Any Immunomodulation

Market Strategy: High-Unmet-Needs - Orphans-First

Forta Bio's "Orphan-first" strategy provides a capital-efficient path to market in areas of high unmet need, establishing a foothold for expansion into larger indications. (Based on a net price of $200k/year).

Total Addressable Market by Segment (2030)
Total TAM: $14.2B



Segment	TAM (2030)	Key Market Drivers
Acute Myeloid Leukemia (AML)	$6.3B	Aging population, rising incidence, and adoption of novel targeted therapies.
Primary Mediastinal B-cell Lymphoma (PMBCL)	$0.4B	2.5% of the Non-Hodgkin Lymphoma (NHL) market. High unmet need in a rare orphan indication with growing CAR-T therapy
Aggressive Variant Prostate Cancer (AVPC)	$4.3B	Represents a subset of CRPC with high unmet need and limited effective treatment options. 20% of the Castrate-Resistant
Lupus Nephritis (LN)	$3.2B	New drug approvals and a shift from corticosteroids to targeted biologics.
Total TAM	$14.2B	

Further Expansion into Solid Tumors & Autoimmune Disorders

Forta Bio